BSX · 10-Q · 2026Q2 · Full report
Revenue Performance and Mix
BOSTON SCIENTIFIC CORP · 2026-08-03 · Importance 49 · Surprise 32 · No source text
Second-quarter 2026 net sales increased 7.5% year over year to $5.442 billion, while six-month sales increased 9.5% to $10.646 billion. Organic growth was 7.0% in the quarter and 8.1% for the first six months after excluding foreign-currency effects of 0.5% and 1.4%, respectively. Cardiovascular sales increased 8.3% in the quarter and 10.8% year to date to $7.126 billion, led by AGENT Drug-Coated Balloon and the Farapulse PFA System. MedSurg sales increased 5.9% in the quarter and 6.9% year to date to $3.519 billion, while Neuromodulation grew 12.7% and 14.9%, respectively, and Urology grew only 1.1% and 1.6% because of China volume-based procurement and sacral neuromodulation disruption.
Key facts
- Reported net sales for the three months ended June 30, 2026: $5,442 million, compared to $5,061 million in the three months ended June 30, 2025, an increase of 7.5%. source
- Reported net sales for the six months ended June 30, 2026: $10,646 million, compared to $9,724 million in the six months ended June 30, 2025, an increase of 9.5%. source
- MedSurg net sales for the three months ended June 30, 2026: $1,818 million versus $1,716 million in the prior-year period, reported growth 5.9% and operational growth 5.4%. source
- Cardiovascular net sales for the three months ended June 30, 2026: $3,624 million versus $3,345 million in the prior-year period, reported growth 8.3% and operational growth 7.8%. source
- Net sales operational growth for the three months ended June 30, 2026 was 7.0% after excluding foreign currency impact of (0.5)%. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | +16.9% | Reported net sales for the six months ended June 30, 2026: $10,646 million, compared to $9,724 million in the six months ended June 30,… |
| revenue | positive | realized | +7.0% | Reported net sales for the three months ended June 30, 2026: $5,442 million, compared to $5,061 million in the three months ended June 30,… |
| revenue | positive | realized | +5.1% | Cardiovascular net sales for the three months ended June 30, 2026: $3,624 million versus $3,345 million in the prior-year period, reported… |
| revenue | positive | realized | +1.9% | MedSurg net sales for the three months ended June 30, 2026: $1,818 million versus $1,716 million in the prior-year period, reported growth… |